Cumberland shareholders elect directors, ratify auditor, approve say-on-pay and incentive plan amendment

CUMBERLAND PHARMACEUTICALS INC

Class I directors Krogulski (99.1%) and Young (90.7%) elected; Class II director Brown (98.6%) elected.
Ratification of FORVIS as auditor for 2023 received 99.1% votes in favor.
Advisory say-on-pay resolution approved with 89.9% votes in favor.
Amendment to 2007 Long-Term Incentive Plan approved with 75.0% votes in favor.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

CUMBERLAND PHARMACEUTICALS INC shareholders approved Approval of an amendment to the Amended and Restated 2007 Long-Term Incentive Compensation Plan at the 2023-04-25 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

Approve an amendment to the amended and restated 2007 long-term incentive compensation plan 6,869,796 2,286,706 — 26,353 75.0%

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

CUMBERLAND PHARMACEUTICALS INC shareholders approved Resolution regarding compensation of the named executive officers at the 2023-04-25 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

Resolution regarding compensation of named officers 8,228,888 926,046 — 27,921 89.9%

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

CUMBERLAND PHARMACEUTICALS INC shareholders approved Ratification of the appointment of FORVIS, LLP as independent registered public accounting firm for the year ending December 31, 2023 at the 2023-04-25 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

Appointment of FORVIS, LLP as our independent registered public accounting firm for the year ending December 31, 2023 11,474,731 107,830 — 17,830 99.1%

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.95

CUMBERLAND PHARMACEUTICALS INC shareholders approved Election of Directors at the 2023-04-25 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-04-25

Exact text from the filing

The voting results were as follows: For Against Withheld Abstentions % of Votes in Favor Kenneth J. Krogulski 9,100,390 — 82,465 — 99.1% Caroline R. Young 8,326,006 — 856,849 — 90.7% Martin S. Brown, Jr. 9,053,642 — 129,213 — 98.6%

View on SEC.gov

Browse all shareholder votes →

CUMBERLAND PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001628280-23-014265

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.